Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Peter Stæhr"'
Autor:
Shichang Miao, Peter Staehr, Ezra Tai, Borje Darpo, Hongqi Xue, Danielle Armas, Kenneth Webster, Rajneet K. Oberoi
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 7, Pp n/a-n/a (2024)
Abstract This phase I thorough QTc, double‐blind, randomized, placebo‐ and positive‐controlled, parallel group, multiple‐dose study evaluated avacopan's effect on cardiac repolarization using concentration‐QTc (C‐QTc) as the primary analy
Externí odkaz:
https://doaj.org/article/a9cf4106b51344e988533b466eaadf9d
Autor:
Chris Li, Carolyn Dunlap, Bin Zhao, James Kilgour, null Karen Ebsworth, Peter Staehr, Israel Charo, Thomas Schall, Kavita Sarin, Kathleen Sullivan
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB147
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Primary Focal Segmental Glomerulosclerosis (FSGS) is the most common primary glomerular disease in patients with end stage renal disease in the United States. Current treatment regimens target reduction in proteinuria, but may hav
Autor:
Peter Staehr, Pannipa Suwannasom, Roseann White, Bernard Chevalier, John B. Hernandez, Angel Cequier, Dariusz Dudek, Robbert J. de Winter, Manel Sabaté, Maik J. Grundeken, Yuki Ishibashi, Susan Veldhof, Adrianus J. van Boven, Yoshinobu Onuma, Patrick W. Serruys, Hector M. Garcia-Garcia, Jan J. Piek, Wai-Fung Cheong, Michael Haude, Andreas Baumbach, Steffen Helqvist, Joanna J. Wykrzykowska
Publikováno v:
European Heart Journal-Quality of Care and Clinical Outcomes, 2(2), 108-116. Oxford University Press
In the ABSORB II trial, comparing Absorb™ bioresorbable vascular scaffold with metallic XIENCE™ everolimus-eluting stent (EES), a difference was found in site-reported new or worsening angina using adverse event (AE) reporting. However, the clini
Autor:
Stephen G. Ellis, Maureen Kennedy, Gregg W. Stone, Louis Cannon, Peter Staehr, Dean J. Kereiakes, Karine Piard-Ruster, David G. Rizik
Publikováno v:
Journal of the American College of Cardiology. 66:2467-2469
The Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) is designed to reduce chronic adverse cardiovascular events that may occur from the permanent presence of a metallic stent and/or durable polymer. The systemi
Autor:
Julia Zack, Justus Bingham, Peter Staehr, Xuegong Wang, Yu L. Ho, Luiz Belardinelli, Arvinder Dhalla
Publikováno v:
The Journal of Clinical Pharmacology. 53:385-392
GS-9667, a new selective, partial agonist of the A(1) adenosine receptor (AR), may represent an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA). The objectives of the studies were to evaluate the e
Autor:
David Rivas, Peter Staehr, Rajneesh Nath, Suneel K. Gupta, Joseph W. Aquilina, Nishit B. Modi
Publikováno v:
The Journal of Clinical Pharmacology. 49:634-642
Selective serotonin reuptake inhibitors (SSRIs) may be associated with electrocardiographic effects. The electrocardiographic pharmacodynamics of dapoxetine, a short-acting SSRI being developed for the treatment of premature ejaculation, are compared
Autor:
David G, Rizik, Louis, Cannon, Gregg W, Stone, Maureen, Kennedy, Karine, Piard-Ruster, Peter, Staehr, Stephen G, Ellis, Dean J, Kereiakes
Publikováno v:
Journal of the American College of Cardiology. 66(21)
Autor:
Junji Yajima, Sherry Cao, Gregg W. Stone, Nobuhisa Hagiwara, Takeshi Kimura, Yoshinobu Onuma, Peter Staehr, Kazuaki Mitsudo, Toshiya Muramatsu, Hajime Kusano, Wai Fung Cheong, Sunao Nakamura, Masahisa Yamane, Ken Kozuma, Shih-Wa Ying, Jeffrey J. Popma, Shigeru Saito, Patrick W. Serruys, Kengo Tanabe
Publikováno v:
European Heart Journal, 36(47), 3332-3342. Oxford University Press
Aims Theoretically, bioresorbable vascular scaffolds (BVSs) may provide superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective as metallic DESs prior to complete bioreso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::421b41eb7ed9d6446ee4c3869c56bd83
https://pure.eur.nl/en/publications/9ac34f11-7645-4f39-8af4-3cd8eedfb10b
https://pure.eur.nl/en/publications/9ac34f11-7645-4f39-8af4-3cd8eedfb10b
Autor:
Maik J. Grundeken, Lei Peng, Susan Veldhof, Bernard Chevalier, Peter Staehr, Angel Cequier, Andrés Iñiguez, Luc Wasungu, Didier Carrié, Michael Haude, René J van der Schaaf, Marcello Dominici, Yoshinobu Onuma, Hector M. Garcia-Garcia, Patrick W. Serruys, Dariusz Dudek, Yuki Ishibashi
Publikováno v:
Lancet (UK), 385(9962), 43-54. Elsevier Ltd.
Lancet, 385(9962), 43-54. Elsevier Limited
Lancet, 385(9962), 43-54. Elsevier Limited
Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for treatment for coronary artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled trial we aimed to compare an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c3db74b9e3c0601827ab3472dd1b80
https://ruj.uj.edu.pl/xmlui/handle/item/123130
https://ruj.uj.edu.pl/xmlui/handle/item/123130